Gestational Trophoblastic Disease: Types, Symptoms, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Gestational trophoblastic disease (GTD) is a spectrum of tumors arising from placental trophoblastic tissue after pregnancy. Types include hydatidiform mole (complete and partial), gestational trophoblastic neoplasia (GTN: invasive mole, choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor). Molar pregnancy occurs in approximately 1 in 1,000-2,000 pregnancies in Western countries. GTN uniquely produces beta-hCG, which serves as an almost perfect tumor marker for diagnosis, treatment monitoring, and surveillance.

Complete moles arise from androgenetic diploidy (empty egg fertilized by two sperm, or one sperm that duplicates); partial moles are triploid from two sperm fertilizing a normal egg. Risk factors include maternal age extremes (teenagers and women over 40 have highest risk), prior molar pregnancy (1-2% recurrence risk), Asian ethnicity, nutritional deficiency (carotene and folate), and blood type A or AB. Choriocarcinoma can follow any type of pregnancy: normal delivery (50%), spontaneous abortion (25%), molar pregnancy (25%), or ectopic pregnancy.

Vaginal bleeding in the first trimester is the most common presenting symptom of hydatidiform mole. Uterine size larger than expected for gestational age, hyperemesis gravidarum (from high hCG levels stimulating nausea), early preeclampsia (before 20 weeks), and absent fetal heart sounds are classic features. Grape-like vesicles passed vaginally are pathognomonic but rare. Beta-hCG levels are markedly elevated, often greater than 100,000 mIU/mL. Respiratory symptoms and neurological symptoms indicate pulmonary and brain metastases from GTN.

Quantitative serum beta-hCG is mandatory for all suspected molar pregnancies and to monitor GTN response to treatment. Transvaginal ultrasound shows the classic snowstorm appearance (complete mole) or heterogeneous uterine content (partial mole). Post-evacuation GTN is diagnosed by beta-hCG plateau, rise, or histological confirmation. CT chest and abdomen and brain MRI complete staging for GTN. WHO/FIGO combined scoring system (0-12+ score incorporating previous pregnancy type, interval, hCG level, tumor size, metastatic sites, prior treatment) stratifies GTN as low-risk (score less than 7) or high-risk (score 7 or greater).

Hydatidiform mole: suction curettage (uterine evacuation) under ultrasound guidance; oxytocin after dilation; weekly beta-hCG monitoring until normal for 3 consecutive weeks. Low-risk GTN (WHO score less than 7): single-agent methotrexate (intramuscular or oral pulsed) or actinomycin-D achieves over 99% cure. High-risk GTN: EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) every 2 weeks; EMA-EP for EMA-CO-refractory disease. Ultra-high risk GTN (brain metastases, liver metastases, score greater than 12): induction EP (etoposide-cisplatin) before EMA-CO. Hysterectomy may be performed in older patients who have completed childbearing.

GTD is among the most curable of all cancers. Hydatidiform mole: virtually 100% resolution after evacuation; 15-20% of complete moles develop GTN requiring treatment. Low-risk GTN: cure rate greater than 99% with single-agent chemotherapy. High-risk metastatic GTN: cure rate greater than 90% with EMA-CO. Brain metastases: cure rate approximately 70-80% with appropriate treatment including intrathecal or whole-brain radiation. Placental site trophoblastic tumor has a lower chemosensitivity than choriocarcinoma, with surgical resection being critical for cure.

No prevention for molar pregnancy is established. Patients with prior molar pregnancy should undergo genetic counseling and be aware of the approximately 1-2% recurrence risk in future pregnancies; early ultrasound with beta-hCG measurement at 8-10 weeks gestation is recommended. Genetic testing may identify biparental complete mole (NLRP7 or KHDC3L mutations), a rare hereditary condition with very high molar pregnancy recurrence rates. Women completing GTN treatment should defer pregnancy for a minimum of 6 months after hCG normalization to allow accurate relapse surveillance.